Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2000;87:705-709

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kilts, J. D.
Right arrow Articles by Kwatra, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kilts, J. D.
Right arrow Articles by Kwatra, M. M.
Related Collections
Right arrow Biochemistry and metabolism
Right arrow Congestive
Right arrow Receptor pharmacology
(Circulation Research. 2000;87:705.)
© 2000 American Heart Association, Inc.


Molecular Medicine

ß2-Adrenergic and Several Other G Protein–Coupled Receptors in Human Atrial Membranes Activate Both Gs and Gi

Presented in part at the 1998 Annual Meeting of the American Society of Anesthesiologists, Orlando, Fla, October 17–21, 1998.

Jason D. Kilts, Mark A. Gerhardt, Mark D. Richardson, Gautam Sreeram, G. Burkhard Mackensen, Hilary P. Grocott, William D. White, R. Duane Davis, Mark F. Newman, Joseph G. Reves, Debra A. Schwinn, Madan M. Kwatra

From the Departments of Anesthesiology (J.D.K., M.D.R., G.S., G.B.M., H.P.G., W.D.W., M.F.N., J.G.R., D.A.S., M.M.K.), Pharmacology and Cancer Biology (D.A.S., M.M.K.), and Surgery (R.D.D., D.A.S.), Duke University Medical Center, Durham, NC; and Department of Anesthesiology (M.A.G.), Ohio State University, Columbus, Ohio.

Correspondence to Madan M. Kwatra, PhD, Department of Anesthesiology, 146 Sands Bldg, Box 3094, Duke University Medical Center, Durham, NC 27710. E-mail kwatr001{at}mc.duke.edu


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Abstract—Cardiac G protein–coupled receptors that couple to G{alpha}s and stimulate cAMP formation (eg, ß-adrenergic, histamine, serotonin, and glucagon receptors) play a key role in cardiac inotropy. Recent studies in rodent cardiac myocytes and transfected cells have revealed that one of these receptors, the ß2-adrenergic receptor (AR), also couples to the inhibitory G protein G{alpha}i (activation of which inhibits cAMP formation). If ß2ARs could be shown to couple to G{alpha}i in the human heart, it would have important ramifications, because levels of G{alpha}i increase with age and in failing human heart. Therefore, we investigated whether ß2ARs in the human heart activate G{alpha}i. By photoaffinity labeling human atrial membranes with [32P]azidoanilido-GTP, followed by immunoprecipitation with antibodies specific for G{alpha}i, we found that G{alpha}i is activated by stimulation of ß2ARs but not of ß1ARs. In addition, we found that other G{alpha}s-coupled receptors also couple to G{alpha}i, including histamine, serotonin, and glucagon. When coupling of these receptors to G{alpha}i is disrupted by pertussis toxin, their ability to stimulate adenylyl cyclase is enhanced. These data provide the first evidence that ß2AR and many other G{alpha}s-coupled receptors in human atrium also couple to G{alpha}i and that abolishing the coupling of these receptors to G{alpha}i increases the receptor-mediated adenylyl cyclase activity.


Key Words: human atrial G{alpha}s and G{alpha}i • ß2-adrenergic receptor • cardiac Gs–coupled receptors


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Beta-adrenergic receptors (ßARs), which couple to G{alpha}s and stimulate adenylyl cyclase (AC) activity, play a key role in cardiac function.1 An important recent finding in ßAR signaling is that the rodent cardiac ß2AR couples to both stimulatory (G{alpha}s) and inhibitory (G{alpha}i) G proteins,2 3 4 as does the recombinant ß2AR transiently expressed in HEK293 cells.5 The activation of G{alpha}i by ß2ARs may have important clinical implications because cardiac G{alpha}i levels increase in failing heart6 7 8 and in aging.9 This increase in cardiac G{alpha}i could increase the number of ß2ARs that are coupled to G{alpha}i, resulting in a decrease in cardiac ßAR function seen in older people and in patients with congestive heart failure. However, signaling through cardiac ß2ARs exhibits considerable diversity among mammalian species (for review, see Xiao et al10 ). Therefore, before we implicate the coupling of ß2AR to G{alpha}i as a factor in this observed reduction in cardiac ßAR function, ß2ARs must first be shown to couple to G{alpha}i in the human heart as they do in rodents.

The present study sought to determine whether human cardiac ß2ARs activate G{alpha}i. Using photoaffinity labeling with [32P]azidoanilido-GTP ([32P]AAGTP) followed by immunoprecipitation with antibodies specific for G{alpha}s and G{alpha}i, we show that stimulation of ßARs in human atrial membranes with isoproterenol leads to the activation of both G{alpha}s and G{alpha}i. Whereas both ß1ARs and ß2ARs activate G{alpha}s, only ß2ARs activate G{alpha}i. Interestingly, cardiac G{alpha}i is also activated by stimulation of several other G{alpha}s-coupled receptors including histamine, serotonin, and glucagon. When the coupling of these receptors to G{alpha}i is disrupted by pertussis toxin (PTX), their ability to stimulate AC is enhanced. These data provide the first evidence that ß2ARs and several other G{alpha}s-coupled cardiac G protein–coupled receptors (GPCRs) in human atrium couple to both G{alpha}s and G{alpha}i.


*    Materials and Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Materials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Human Atrial Samples
Human atrial samples were obtained under an Institutional Review Board–approved protocol from 25 patients age 51 to 67 years (mean 57.8±4.9 years) undergoing cardiac surgery involving cardiopulmonary bypass at Duke University Medical Center. A piece of right atrial appendage weighing 60 to 150 mg was obtained at the time of atrial cannulation, frozen immediately in liquid nitrogen, and stored at -80°C. Eleven atrial samples were used solely for photoaffinity labeling experiments, 12 were used solely for AC experiments, and 2 were used for both types of experiments. Ten of the 13 samples used for photoaffinity labeling, and 11 of the 14 samples used for AC assays were taken from patients taking ßAR antagonists. There was no discernible difference in results between patients who received ßAR antagonists and those who did not.

Atrial Membrane Preparation
Atrial samples were homogenized and centrifuged. The membrane pellets were resuspended at 2 to 4 mg protein/mL in either buffer A (containing [in mmol/L] HEPES [pH 7.4] 50, EDTA 1, NaCl 50, and benzamidine 2) for photoaffinity labeling assays or buffer B (containing [in mmol/L] Tris [pH 7.4] 75, MgCl2 12.5, EDTA 2, and benzamidine 1, and [in mg/L] soybean trypsin inhibitor 10, leupeptin 10, and aprotinin 5) for AC assays.

Photoaffinity Labeling With [32P]AAGTP and Immunoprecipitation
[32P]AAGTP was synthesized according to published procedures and purified by thin-layer chromatography on polyethylenimine cellulose (J.T. Baker).11 12 Photoaffinity labeling of human atrial membranes (85 µg protein) was performed using 2 µCi of [32P]AAGTP in a total volume of 60 µL in the presence of various drugs indicated in the figure legends. Immunoprecipitation of photolabeled G{alpha} subunits and subsequent analysis by SDS-PAGE/autoradiography was performed as described previously.11 12

PTX Treatment of Atrial Membranes and AC Assays
PTX (50 ng/µL) was activated by incubation with 100 mmol/L DTT and 0.25% SDS for 30 minutes at 30°C as described previously,13 with minor modifications, and mixed with atrial membranes. A second tube containing the same volumes of all constituents, with the exception of H2O in place of PTX, was treated in the same fashion and used as a control. AC activity was measured according to the method of Salomon et al14 and Johnson and Salomon15 as described previously,16 with the addition of 0.4 mmol/L 3-isobutylmethylxanthine to the reaction mixture.

Statistical Analysis
Results are presented as mean±SD. Because of the large variations in basal activities between patients, the data are reported as percentage change. The statistical significance of agonist stimulation on the incorporation of [32P]AAGTP into G proteins and agonist stimulation of AC were determined by paired t tests on the percentage change from basal. A paired t test was also used to compare AC activities in the control membranes and PTX-treated membranes. To compare the PTX-induced increase in basal, forskolin-stimulated, and ß1AR-stimulated AC activities with the PTX-induced increase in AC stimulation of receptors that couple to both G{alpha}s and G{alpha}i, a repeated-measures mixed-effects general linear regression model was used.17 18 P<0.05 was considered significant for all comparisons.

An expanded Materials and Methods section can be found in an online data supplement available at http://www.circresaha.org.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
*Results
down arrowDiscussion
down arrowReferences
 
ß2ARs, but Not ß1ARs, Stimulate Both G{alpha}s and G{alpha}i in Human Atrial Membranes
As shown in Figure 1Down, stimulation of human atrial ßARs with isoproterenol activates G{alpha}s (both the long and short isoforms)19 and G{alpha}i; this is revealed by increased photoaffinity labeling of these G{alpha} subunits with [32P]AAGTP. On average, isoproterenol significantly increased the incorporation of [32P]AAGTP, to 209±48% of control in G{alpha}s and to 212±33% of control in G{alpha}i. This increase in photoaffinity labeling of both G{alpha}s and G{alpha}i is blocked in the presence of the ß2AR antagonist ICI 118,551, indicating that activation of G{alpha}s and G{alpha}i is mediated through ß2ARs. Importantly, the extent of G{alpha}i activation by isoproterenol in these membranes is similar to that seen after stimulation of prototypical Gi-coupled muscarinic receptors with carbachol (data not shown).



View larger version (31K):
[in this window]
[in a new window]
 
Figure 1. Activation of both G{alpha}s and G{alpha}i by ßARs in human heart. Human atrial membranes were photoaffinity labeled with [32P]AAGTP in the presence of no drug (Basal), isoproterenol (Iso), or isoproterenol and ICI 118,551 (ICI), each drug at 100 µmol/L, as described in Materials and Methods. The photolabeled membranes were immunoprecipitated with either RM/1 antibody (for G{alpha}s) or AS/7 antibody (for G{alpha}i), and immunoprecipitates were subjected to SDS-PAGE followed by autoradiography. G{alpha}s-L and G{alpha}s-S indicate the long and short isoforms of G{alpha}s, respectively. A representative autoradiogram is shown; the experiment was repeated 4 times with similar results.

In rodent hearts, ß2ARs, but not ß1ARs, activate G{alpha}i.2 3 4 To determine whether this is also the case in human heart, we used the following 2 approaches: (1) we stimulated ßARs with agonists selective for either ß1ARs or ß2ARs and (2) we stimulated ßARs with the nonselective agonist isoproterenol in the presence of a ß1AR- or ß2AR-selective antagonist (Figures 2Down and 3Down, respectively). As shown in Figure 2Down, whereas both zinterol (agonist for ß2ARs) and dobutamine (agonist for ß1ARs) stimulate G{alpha}s (to 195±38% and 165±26% of control, respectively), only zinterol stimulates G{alpha}i (to 204±19% of control). Similar results are obtained using ß12-selective antagonists; Figure 3Down shows that stimulation of G{alpha}i by isoproterenol is blocked in the presence of ß2AR-selective antagonist ICI 118,551 but not in the presence of ß1AR-selective antagonist CGP 20712A. Taken together, these data establish that ß2ARs, but not ß1ARs, in human atrial membranes activate G{alpha}i.



View larger version (23K):
[in this window]
[in a new window]
 
Figure 2. ß2AR, but not ß1AR, couples to G{alpha}i. Human atrial membranes were photoaffinity labeled with [32P]AAGTP in the presence of no drug (Basal), 100 µmol/L dobutamine (Dobut, ß1AR agonist), or 100 µmol/L zinterol (Zint, ß2AR agonist) as described in Materials and Methods. Photolabeled membranes were immunoprecipitated with either RM/1 antibody (for G{alpha}s) or AS/7 antibody (for G{alpha}i), and immunoprecipitates were subjected to SDS-PAGE followed by autoradiography. G{alpha}s-L and G{alpha}s-S indicate the long and short isoforms of G{alpha}s, respectively. A representative autoradiogram is shown; the experiment was repeated 3 times with similar results.



View larger version (61K):
[in this window]
[in a new window]
 
Figure 3. Blockade of ß2AR, but not of ß1AR, abolishes isoproterenol-induced stimulation of G{alpha}i. Human atrial membranes were photoaffinity labeled with [32P]AAGTP in the presence of no drug (Basal), isoproterenol (Iso), or Iso and either ICI 118,551 (ICI, ß2AR antagonist) or CGP 20712A (CGP, ß1AR antagonist), each drug at 100 µmol/L, as described in Materials and Methods. The photolabeled membranes were immunoprecipitated with AS/7 antibody (for G{alpha}i), and immunoprecipitates were subjected to SDS-PAGE followed by autoradiography. A representative autoradiogram is shown; the experiment was repeated 3 times with similar results.

Stimulation of Histamine, Serotonin, and Glucagon Receptors in Human Atrial Membranes Also Activates G{alpha}i
In addition to ßARs, cardiac inotropy is also mediated through histamine, serotonin, and glucagon receptors.20 Like ßARs, these receptors stimulate AC through G{alpha}s. Therefore, it was of interest to determine whether these receptors can also activate G{alpha}i. As shown in Figure 4Down, G{alpha}i is strongly activated in the presence of histamine and glucagon and moderately activated in the presence of serotonin. Histamine, glucagon, and serotonin all significantly increase the incorporation of [32P]AAGTP into G{alpha}i, to 189±16%, to 210±58%, and to 121±11% of control, respectively. A selective antagonist for each receptor can block the stimulation of G{alpha}i by that receptor, indicating that activation of G{alpha}i is a consequence of receptor stimulation (Figure 4Down).



View larger version (23K):
[in this window]
[in a new window]
 
Figure 4. Histamine, glucagon, and serotonin receptors couple to G{alpha}i. Human atrial membranes were photoaffinity labeled with [32P]AAGTP in the presence of no drug (Basal) or various agonists, or agonists plus corresponding antagonists, as described in Materials and Methods. Agonists included were isoproterenol (Iso, 100 µmol/L), histamine (Hist, 100 µmol/L), glucagon (Gluc, 50 µmol/L), and serotonin (5-HT, 100 µmol/L). Antagonists included were ICI 118,551 (ICI) for ß2ARs, cimetidine (Cimet) for histamine receptors, des-His1-(Glu9)-glucagon (des-Gluc) for glucagon receptors, and SDZ-205,557 (SDZ) for serotonin receptors (all antagonist concentrations were the same as for the respective agonists). Photolabeled membranes were immunoprecipitated with AS/7 antibody (for G{alpha}i), and immunoprecipitates were subjected to SDS-PAGE followed by autoradiography. A representative autoradiogram is shown; the experiment was repeated 3 times with similar results.

Effect of PTX Treatment on AC Activity
The data of Figures 1 through 4UpUpUpUp indicate that ß2AR and other G{alpha}s-coupled receptors couple to both G{alpha}s and G{alpha}i. Given that stimulation of G{alpha}i-coupled receptors inhibits AC, an obvious next question is whether the disruption of the coupling of these cardiac receptors to G{alpha}i removes this inhibitory component and increases receptor-mediated AC activation. Therefore, we treated human atrial membranes with PTX, which ADP-ribosylates G{alpha}i and disrupts its ability to interact with GPCRs.21 22 These data are shown in Figure 5Down.



View larger version (31K):
[in this window]
[in a new window]
 
Figure 5. PTX treatment of human atrial membranes increases AC activity. Control or PTX-treated human atrial membranes were assayed for AC activity, as described in Materials and Methods. Drugs included were the following (in µmol/L): isoproterenol (Iso, 100), ICI 118,551 (ICI, 100), CGP 20712A (CGP, 100), histamine (Hist, 100), glucagon (Gluc, 50), serotonin (5-HT, 100), and forskolin (Fsk, 50). Basal AC activity ranged from 11 to 254 pmol cAMP/mg protein per 15 minutes. Data are expressed as percentage of basal AC activity in control atrial membranes. The experiment was repeated 4 times with similar results. *P<0.05 compared with basal AC activity in control membranes; **P<0.05 compared with AC stimulation by same drug in control membranes.

In control membranes, AC activity increases with stimulation of ßARs by isoproterenol to 254±46% of control. Selective activation of ß1ARs (by inclusion of both isoproterenol and the ß2AR antagonist ICI 118,551) stimulates AC to 178±27% of control, whereas selective activation of ß2ARs (by inclusion of both isoproterenol and the ß1AR antagonist CGP 20712A) stimulates AC to 140±22% of control. In addition, histamine and glucagon receptors stimulate AC to 145±31% and 156±48% of control, respectively; the stimulation of AC by serotonin (105±16% of control) was not statistically significant. Forskolin, a direct activator of AC, stimulates AC to 1104±326% of control. These data on AC stimulation in human atrium are similar to that reported by other investigators.23 24

In PTX-treated membranes, basal AC activity is significantly increased (to 442±266% of control), as is AC activity stimulated by agonists of various G{alpha}s-coupled receptors (ßARs, 1091±676% of control; ß1ARs, 668±252%; ß2ARs, 907±393%; histamine receptors, 787±486%; glucagon receptors, 895±505%; and serotonin receptors, 852±448%) and by forskolin (1896±543% of control) (Figure 5Up). Although PTX treatment increases AC activity under every condition tested, there is a greater increase in AC stimulation through receptors that also couple to G{alpha}i. The PTX-induced increase in basal, forskolin-stimulated, and ß1AR-stimulated AC activities ranged from 1.7- to 4.4-fold, whereas the PTX-induced increase in AC activity after stimulation of receptors that couple to both G{alpha}s and G{alpha}i ranged from 5.4- to 8.1-fold, and the difference between the 2 groups is statistically significant (P<0.05). These results indicate that disruption of the coupling of G{alpha}s-coupled receptors to G{alpha}i enhances their ability to stimulate AC. Note that whereas stimulation of AC by serotonin in control membranes is not significant, it is highly significant in PTX-treated membranes.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
*Discussion
down arrowReferences
 
The main findings of this study are that, in human atrial membranes, (1) ß2AR activates both G{alpha}s and G{alpha}i; (2) both G{alpha}s and G{alpha}i are also activated by several other receptors including glucagon, histamine, and serotonin; and (3) the coupling of these G{alpha}s-coupled receptors to G{alpha}i is functional, given that AC stimulation by these receptors is increased by PTX treatment. These findings add a new level of complexity into the signaling of human cardiac inotropic receptors.

The finding that ß2AR and other G{alpha}s-coupled receptors also couple to G{alpha}i is an important development. Initially, it was thought that G{alpha}s-coupled receptors and G{alpha}i-coupled receptors are activated by distinct hormones. For example, G{alpha}s-coupled ßARs are stimulated by the sympathetic hormones norepinephrine and epinephrine, and G{alpha}i-coupled muscarinic receptors are activated by the parasympathetic hormone acetylcholine. However, this apparently logical signaling scheme is complicated by the recent finding of Xiao et al2 that cardiac ß2ARs also activate G{alpha}i. Specifically, they showed that PTX pretreatment in rat cardiac myocytes increases ß2AR-mediated responses, including increases in contraction amplitudes, calcium influx, and Cai transients. Their finding has been supplemented by additional data showing potentiation of ß2AR functional responses by PTX as well as a direct labeling of G{alpha}i proteins due to ß2AR stimulation in rat and mouse cardiac myocytes.3 5 25 In contrast, ß1AR responses are not sensitive to PTX, and direct photoaffinity labeling of mouse heart membranes did not detect any ß1AR-mediated G{alpha}i activation.3 In the present study, we show that a similar situation occurs in human atrial tissue. More importantly, we find that G{alpha}i is also activated by stimulation of glucagon, histamine, and serotonin receptors. Thus, coupling to G{alpha}i is not a unique property of cardiac ß2ARs. In fact, with the exception of ß1ARs, coupling to both G{alpha}s and G{alpha}i appears to be a general property of cardiac G{alpha}s-coupled receptors in human atrial tissue.

Having demonstrated that ß2AR and several other G{alpha}s-coupled receptors also activate G{alpha}i, we sought to determine whether disruption of G{alpha}i increases AC stimulation through G{alpha}s-coupled receptors. The data of Figure 5Up show that disruption of G{alpha}i causes an increase in AC activity under every condition tested. An increase in basal and forskolin-stimulated AC activity after PTX treatment implies that there exists a tonic inhibition of AC by G{alpha}i. This tonic inhibition of AC by G{alpha}i may also be responsible for the observed increase in ß1AR-stimulated AC activity after PTX treatment. Compared with the effect of PTX on AC stimulation through ß1ARs, which do not couple to G{alpha}i, the effect of PTX on AC stimulation through ß2ARs (and other G{alpha}s-coupled receptors that also couple to G{alpha}i) is greater. These results indicate that coupling of G{alpha}s-coupled receptors to G{alpha}i has functional consequences at the level of AC. This conclusion, however, disagrees with similar studies in rat myocytes in which PTX treatment had no significant effect on ß2AR-mediated cAMP formation26 or activation of protein kinase A.25 On the basis of these data, Xiao et al10 present a model depicting that the cross talk between the pathways stimulated by ß2AR coupling to G{alpha}s and G{alpha}i occurs at a point distal to AC and protein kinase A. Clearly, this rat model is not supported by our data with human atrial membranes.

The physiological function of the coupling of G{alpha}s-coupled receptors to G{alpha}i also remains to be fully evaluated. The ability of G{alpha}s-coupled receptors to also activate G{alpha}i raises the possibility that this pathway may become exaggerated when G{alpha}i levels are increased in both failing and aged hearts. Indeed, a decrease in ßAR function in failing human heart and in the elderly has been observed.27 28 In addition to ßARs, histamine and serotonin receptors show decreased ability to stimulate AC in failing heart.23 Whether this decrease in AC stimulation through G{alpha}s-coupled receptors in failing heart and aging is the result of an enhanced coupling to G{alpha}i remains to be determined. Interestingly, it was recently shown that activation of G{alpha}i by ß2AR stimulation opposes the apoptotic action of ß1AR stimulation in rat cardiac myocytes, and it was suggested that an increased activation of Gi may be of therapeutic value.29

In summary, the present study provides the first evidence that ß2ARs and several other GPCRs in human atrial tissue couple to both G{alpha}s and G{alpha}i; disruption of the coupling of these receptors to G{alpha}i enhances their ability to stimulate AC.


*    Acknowledgments
 
This research was supported by NIH Grants AG15817 (to M.M.K.), HL57447 (to D.A.S. and M.M.K.), AG00745 (to D.A.S.), and 2-T32-AG00029 (to M.D.R.), and GCRC759, as well as a Foundation for Anesthesia Education and Research grant (to M.A.G.). We thank Dr David Kellogg of Duke University for editorial assistance. We thank Wayne Cohen, Kelli Colgan, Keinya Lee, and Scott Lee for their efforts in the collection of tissue samples.

Received April 14, 2000; revision received August 21, 2000; accepted August 21, 2000.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
up arrowDiscussion
*References
 
1. Steinberg SF. The molecular basis for distinct ß-adrenergic receptor subtype actions in cardiomyocytes. Circ Res. 1999;85:1101–1111.[Free Full Text]

2. Xiao R-P, Ji X, Lakatta EG. Functional coupling of the ß2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol. 1995;47:322–329.[Abstract]

3. Xiao R-P, Avdonin P, Zhou Y-Y, Cheng H, Akhter SA, Eschenhagen T, Lefkowitz RJ, Koch WJ, Lakatta EG. Coupling of ß2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. Circ Res. 1999;84:43–52.[Abstract/Free Full Text]

4. Zou Y, Komuro I, Yamazaki T, Kudoh S, Uozumi H, Kadowaki T, Yazaki Y. Both Gs and Gi proteins are critically involved in isoproterenol-induced cardiomyocyte hypertrophy. J Biol Chem. 1999;274:9760–9770.[Abstract/Free Full Text]

5. Daaka Y, Luttrell LM, Lefkowitz RJ. Switching of the coupling of the ß2-adrenergic receptor to different G proteins by protein kinase A. Nature. 1997;390:88–91.[Medline] [Order article via Infotrieve]

6. Bohm M, Gierschik P, Jakobs KH, Pieske B, Schnabel P, Ungerer M, Erdmann E. Increase of Gi{alpha} in human hearts with dilated but not ischemic cardiomyopathy. Circulation. 1990;82:1249–1265.[Abstract/Free Full Text]

7. Bohm M, Eschenhagen T, Gierschik P, Larisch K, Lensche H, Mende U, Schmitz W, Schnabel P, Scholz H, Steinfath M, Erdmann E. Radioimmunochemical quantification of Gi{alpha} in right and left ventricles from patients with ischaemic and dilated cardiomyopathy and predominant left ventricular failure. J Mol Cell Cardiol. 1994;26:133–149.[Medline] [Order article via Infotrieve]

8. Bohm M, Kirchmayr R, Erdmann E. Myocardial Gi{alpha}-protein levels in patients with hypertensive cardiac hypertrophy, ischemic heart disease and cardiogenic shock. Cardiovasc Res. 1995;30:611–618.[Medline] [Order article via Infotrieve]

9. Brodde O-E, Zerkowski H-R, Schranz D, Broede-Sitz A, Michel-Reher M, Schafer-Beisenbusch E, Piotrowski JA, Oelert H. Age-dependent changes in the ß-adrenoceptor-G-protein(s)-adenylyl cyclase system in human right atrium. J Cardiovasc Pharmacol. 1995;26:20–26.[Medline] [Order article via Infotrieve]

10. Xiao R-P, Cheng H, Zhou Y-Y, Kuschel M, Lakatta EG. Recent advances in cardiac ß2-adrenergic signal transduction. Circ Res. 1999;85:1092–1100.[Abstract/Free Full Text]

11. Offermanns S, Schultz G, Rosenthal W. Identification of receptor-activated G proteins with photoreactive GTP analog [{alpha}-32P]GTP azidoanilide. Methods Enzymol. 1991;195:286–301.[Medline] [Order article via Infotrieve]

12. Roush ED, Kwatra MM. Human substance P receptor expressed in Chinese hamster ovary cells directly activates G{alpha}q/11, G{alpha}s, and G{alpha}o. FEBS Lett. 1998;428:291–294.[Medline] [Order article via Infotrieve]

13. Niroomand F, Mura RA, Piacentini L, Kübler W. Opioid receptor agonists activate pertussis toxin-sensitive G proteins and inhibit adenylyl cyclase in canine cardiac sarcolemma. Naunyn Schmiedebergs Arch Pharmacol. 1996;354:643–649.[Medline] [Order article via Infotrieve]

14. Salomon Y, Londos C, Rodbell M. A highly sensitive adenylate cyclase assay. Anal Biochem. 1974;58:541–548.[Medline] [Order article via Infotrieve]

15. Johnson RA, Salomon Y. Assay of adenylyl cyclase catalytic activity. Methods Enzymol. 1991;195:3–21.[Medline] [Order article via Infotrieve]

16. Booth JV, Landolfo KP, Chesnut LC, Bennett-Guerrero E, Gerhardt MA, Atwell DM, El-Moalem HE, Stafford Smith M, Funk BL, Kuhn CM, Kwatra MM, Schwinn DA. Acute depression of myocardial ß-adrenergic receptor signaling during cardiopulmonary bypass. Anesthesiology. 1998;89:602–611.[Medline] [Order article via Infotrieve]

17. Littell RC, Milliken GA, Stroup WW, Wolfinger RD. SAS® System for Mixed Models. Cary, NC: SAS Institute, Inc;1996:87–135.

18. Westfall PH, Tobias RD, Rom D, Wolfinger RD, Hochberg Y. Multiple Comparisons and Multiple Tests Using the SAS® System. Cary, NC: SAS Institute, Inc;1999:203–227.

19. Monteith MS, Wang T, Brown MJ. Differences in transcription and translation of long and short Gs{alpha}, the stimulatory G-protein, in human atrium. Clin Sci. 1995;89:487–495.[Medline] [Order article via Infotrieve]

20. Brodde O-E, Michel MC, Zerkowski H-R. Signal transduction mechanisms controlling cardiac contractility and their alterations in chronic heart failure. Cardiovasc Res. 1995;30:570–584.[Medline] [Order article via Infotrieve]

21. Gilman AG. Guanine nucleotide-binding regulatory proteins and dual control of adenylate cyclase. J Clin Invest. 1984;73:1–4.

22. Moss J, Bruni P, Hsia JA, Tsai S-C, Watkins PA, Halpern JL, Burns DL, Kanaho Y, Chang PP, Hewlett EL, Vaughan M. Pertussis toxin-catalyzed ADP-ribosylation: effects on the coupling of inhibitory receptors to the adenylate cyclase system. J Recept Res. 1984;4:459–474.[Medline] [Order article via Infotrieve]

23. Brodde O-E, Vogelsang M, Broede A, Michel-Reher M, Beisenbusch-Schafer E, Hakim K, Zerkowski HR. Diminished responsiveness of Gs-coupled receptors in severely failing human hearts: no difference in dilated versus ischemic cardiomyopathy. J Cardiovasc Pharmacol. 1998;31:585–594.[Medline] [Order article via Infotrieve]

24. Zerkowski HR, Broede A, Kunde K, Hillemann S, Schafer E, Vogelsang M, Michel MC, Brodde O-E. Comparison of the positive inotropic effects of serotonin, histamine, angiotensin II, endothelin and isoprenaline in the isolated human right atrium. Naunyn Schmiedebergs Arch Pharmacol. 1993;347:347–352.[Medline] [Order article via Infotrieve]

25. Kuschel M, Zhou Y-Y, Cheng H, Zhang S-J, Chen Y, Lakatta EG, Xiao R-P. Gi protein-mediated functional compartmentalization of cardiac ß2-adrenergic signaling. J Biol Chem. 1999;274:22048–22052.[Abstract/Free Full Text]

26. Zhou YY, Cheng H, Bogdanov KY, Hohl C, Altschuld R, Lakatta EG, Xiao R-P. Localized cAMP-dependent signaling mediates ß2-adrenergic modulation of cardiac excitation-contraction coupling. Am J Physiol. 1997;273:H1611–H1618.[Abstract/Free Full Text]

27. Bristow MR, Ginsburg R, Minobe WA, Cubicciotti RS, Sageman WE, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and ß-adrenergic receptor density in failing human hearts. N Engl J Med. 1982;307:205–211.[Abstract]

28. Vestal RE, Wood AJ, Shand DG. Reduced ß-adrenoceptor sensitivity in the elderly. Clin Pharmacol Exp Ther. 1979;26:181–186.

29. Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of ß1- and ß2-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation. 1999;100:2210–2212.[Abstract/Free Full Text]




This article has been cited by other articles:


Home page
J. Physiol.Home page
M. R. Pabbidi, X. Ji, A. M. Samarel, and S. L. Lipsius
Laminin enhances \#946;2-adrenergic receptor stimulation of L-type Ca2+ current via cytosolic phospholipase A2 signalling in cat atrial myocytes
J. Physiol., October 15, 2009; 587(20): 4785 - 4797.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
G. S. Lynch and J. G. Ryall
Role of {beta}-Adrenoceptor Signaling in Skeletal Muscle: Implications for Muscle Wasting and Disease
Physiol Rev, April 1, 2008; 88(2): 729 - 767.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
X.-H. Zhang, G.-R. Li, and J.-P. Bourreau
The effect of adrenomedullin on the L-type calcium current in myocytes from septic shock rats: signaling pathway
Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2888 - H2893.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
A. Ben-Shlomo, O. Pichurin, N. J. Barshop, K. A. Wawrowsky, J. Taylor, M. D. Culler, V. Chesnokova, N.-A. Liu, and S. Melmed
Selective Regulation of Somatostatin Receptor Subtype Signaling: Evidence for Constitutive Receptor Activation
Mol. Endocrinol., October 1, 2007; 21(10): 2565 - 2578.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. N. Ebert and D. G. Taylor
Catecholamines and development of cardiac pacemaking: An intrinsically intimate relationship
Cardiovasc Res, December 1, 2006; 72(3): 364 - 374.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
S. Mittra and J.-P. Bourreau
Gs and Gi coupling of adrenomedullin in adult rat ventricular myocytes
Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H1842 - H1847.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. M. Filipeanu, F. Zhou, M. L. Lam, K. E. Kerut, W. C. Claycomb, and G. Wu
Enhancement of the Recycling and Activation of beta-Adrenergic Receptor by Rab4 GTPase in Cardiac Myocytes
J. Biol. Chem., April 21, 2006; 281(16): 11097 - 11103.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
R. Germack and J. M. Dickenson
Induction of {beta}3-Adrenergic Receptor Functional Expression following Chronic Stimulation with Noradrenaline in Neonatal Rat Cardiomyocytes
J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 392 - 402.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
E.J.F. Danson, Y.H. Zhang, C.E. Sears, A.R. Edwards, B. Casadei, and D.J. Paterson
Disruption of inhibitory G-proteins mediates a reduction in atrial {beta}-adrenergic signaling by enhancing eNOS expression
Cardiovasc Res, September 1, 2005; 67(4): 613 - 623.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Cell Physiol.Home page
M. Gallego, R. Setien, L. Puebla, M. d. C. Boyano-Adanez, E. Arilla, and O. Casis
{alpha}1-Adrenoceptors stimulate a G{alpha}s protein and reduce the transient outward K+ current via a cAMP/PKA-mediated pathway in the rat heart
Am J Physiol Cell Physiol, March 1, 2005; 288(3): C577 - C585.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
L. Barki-Harrington, C. Perrino, and H. A Rockman
Network integration of the adrenergic system in cardiac hypertrophy
Cardiovasc Res, August 15, 2004; 63(3): 391 - 402.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
S. Pepe, O. W.V van den Brink, E. G Lakatta, and R.-P. Xiao
Cross-talk of opioid peptide receptor and {beta}-adrenergic receptor signalling in the heart
Cardiovasc Res, August 15, 2004; 63(3): 414 - 422.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
A. J. Rashid, B. F. O'Dowd, and S. R. George
Minireview: Diversity and Complexity of Signaling through Peptidergic G Protein-Coupled Receptors
Endocrinology, June 1, 2004; 145(6): 2645 - 2652.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
M. W. Sanders, G. E. Fazzi, G. M.J. Janssen, P. W. de Leeuw, C. E. Blanco, and J. G.R. De Mey
Reduced Uteroplacental Blood Flow Alters Renal Arterial Reactivity and Glomerular Properties in the Rat Offspring
Hypertension, June 1, 2004; 43(6): 1283 - 1289.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. F. Heubach, U. Ravens, and A. J. Kaumann
Epinephrine Activates Both Gs and Gi Pathways, but Norepinephrine Activates Only the Gs Pathway through Human {beta}2-Adrenoceptors Overexpressed in Mouse Heart
Mol. Pharmacol., May 1, 2004; 65(5): 1313 - 1322.
[Abstract] [Full Text]


Home page
Mol. Pharmacol.Home page
C. Pavoine, N. Behforouz, C. Gauthier, S. Le Gouvello, F. Roudot-Thoraval, C. R. Martin, A. Pawlak, C. Feral, N. Defer, R. Houel, et al.
{beta}2-Adrenergic Signaling in Human Heart: Shift from the Cyclic AMP to the Arachidonic Acid Pathway
Mol. Pharmacol., November 1, 2003; 64(5): 1117 - 1125.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
R.-P. Xiao, S.-J. Zhang, K. Chakir, P. Avdonin, W. Zhu, R. A. Bond, C. W. Balke, E. G. Lakatta, and H. Cheng
Enhanced Gi Signaling Selectively Negates {beta}2-Adrenergic Receptor (AR)- but Not {beta}1-AR-Mediated Positive Inotropic Effect in Myocytes From Failing Rat Hearts
Circulation, September 30, 2003; 108(13): 1633 - 1639.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
L. A. Hu, W. Chen, N. P. Martin, E. J. Whalen, R. T. Premont, and R. J. Lefkowitz
GIPC Interacts with the {beta}1-Adrenergic Receptor and Regulates {beta}1-Adrenergic Receptor-mediated ERK Activation
J. Biol. Chem., July 3, 2003; 278(28): 26295 - 26301.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
V. O. Rybin, E. Pak, S. Alcott, and S. F. Steinberg
Developmental Changes in {beta}2-Adrenergic Receptor Signaling in Ventricular Myocytes: the Role of Gi proteins and Caveolae Microdomains
Mol. Pharmacol., June 1, 2003; 63(6): 1338 - 1348.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
Y.-S. Bae, T. G. Lee, J. C. Park, J. H. Hur, Y. Kim, K. Heo, J.-Y. Kwak, P.-G. Suh, and S. H. Ryu
Identification of a Compound That Directly Stimulates Phospholipase C Activity
Mol. Pharmacol., May 1, 2003; 63(5): 1043 - 1050.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
T. Cesetti, J. M. Hernandez-Guijo, P. Baldelli, V. Carabelli, and E. Carbone
Opposite Action of beta 1- and beta 2-Adrenergic Receptors on CaV1 L-Channel Current in Rat Adrenal Chromaffin Cells
J. Neurosci., January 1, 2003; 23(1): 73 - 83.
[Abstract] [Full Text] [PDF]


Home page
Cardiovasc ResHome page
R. F. Bosch, A. C. Schneck, J. Kiehn, W. Zhang, A. Hambrock, B. W. Eigenberger, N. Rub, J. Gogel, C. Mewis, L. Seipel, et al.
{beta}3-Adrenergic regulation of an ion channel in the heart--inhibition of the slow delayed rectifier potassium current IKs in guinea pig ventricular myocytes
Cardiovasc Res, December 1, 2002; 56(3): 393 - 403.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
J. T. Auman, F. J. Seidler, and T. A. Slotkin
beta -Adrenoceptor control of G protein function in the neonate: determinant of desensitization or sensitization
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2002; 283(5): R1236 - R1244.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. D. Kilts, T. Akazawa, M. D. Richardson, and M. M. Kwatra
Age Increases Cardiac Galpha i2 Expression, Resulting in Enhanced Coupling to G Protein-coupled Receptors
J. Biol. Chem., August 16, 2002; 277(34): 31257 - 31262.
[Abstract] [Full Text] [PDF]


Home page
J. Physiol.Home page
E. N Dedkova, Y. Gao Wang, L. A Blatter, and S. L Lipsius
Nitric oxide signalling by selective {beta}2-adrenoceptor stimulation prevents ACh-induced inhibition of {beta}2-stimulated Ca2+ current in cat atrial myocytes
J. Physiol., August 1, 2002; 542(3): 711 - 723.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. Gong, H. Sun, W. J. Koch, T. Rau, T. Eschenhagen, U. Ravens, J. F. Heubach, D. L. Adamson, and S. E. Harding
Specific {beta}2AR Blocker ICI 118,551 Actively Decreases Contraction Through a Gi-Coupled Form of the {beta}2AR in Myocytes From Failing Human Heart
Circulation, May 28, 2002; 105(21): 2497 - 2503.
[Abstract] [Full Text] [PDF]


Home page
JGPHome page
Y. G. Wang, E. N. Dedkova, S. F. Steinberg, L. A. Blatter, and S. L. Lipsius
{beta}2-Adrenergic Receptor Signaling Acts via No Release to Mediate Ach-Induced Activation of Atp-Sensitive K+ Current in Cat Atrial Myocytes
J. Gen. Physiol., January 1, 2002; 119(1): 69 - 82.
[Abstract] [Full Text] [PDF]


Home page
Sci SignalHome page
R.-P. Xiao
{beta}-Adrenergic Signaling in the Heart: Dual Coupling of the {beta}2-Adrenergic Receptor to Gs and Gi Proteins
Sci. Signal., October 16, 2001; 2001(104): re15 - re15.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
L. H. Opie and M. N. Sack
Enhanced Angiotensin II Activity in Heart Failure : Reevaluation of the Counterregulatory Hypothesis of Receptor Subtypes
Circ. Res., April 13, 2001; 88(7): 654 - 658.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
R.-P. Xiao
Cell Logic for Dual Coupling of a Single Class of Receptors to Gs and Gi Proteins
Circ. Res., October 13, 2000; 87(8): 635 - 637.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M.-C. Wellner-Kienitz, K. Bender, and L. Pott
Overexpression of beta 1 and beta 2 Adrenergic Receptors in Rat Atrial Myocytes. DIFFERENTIAL COUPLING TO G PROTEIN-GATED INWARD RECTIFIER K+ CHANNELS VIA Gs AND Gi/o
J. Biol. Chem., September 28, 2001; 276(40): 37347 - 37354.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kilts, J. D.
Right arrow Articles by Kwatra, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kilts, J. D.
Right arrow Articles by Kwatra, M. M.
Related Collections
Right arrow Biochemistry and metabolism
Right arrow Congestive
Right arrow Receptor pharmacology